MAM
ARRY

Meeder Asset Management’s Array Biopharma Inc ARRY Stock Holding History

Meeder Asset Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-7,378
Closed -$341K – 2356
2019
Q2 		$341K Sell
7,378
-22,691
-75% -$637K 0.02% 469
2019
Q1 		$732K Buy
30,069
+27,972
+1,334% +$582K 0.06% 305
2018
Q4 		$30K Buy
2,097
+1,812
+636% +$27.5K ﹤0.01% 949
2018
Q3 		$4K Sell
285
-779
-73% -$11.9K ﹤0.01% 1385
2018
Q2 		$17.9K Buy
1,064
+327
+44% +$5.2K ﹤0.01% 990
2018
Q1 		$12K Buy
+737
New +$11.8K ﹤0.01% 1027
2017
Q3 		– Sell
-2,129
Closed -$18K – 1827
2017
Q2 		$18K Buy
2,129
+8
+0.4% +$65 ﹤0.01% 854
2017
Q1 		$19K Buy
2,121
+1,657
+357% +$17.6K ﹤0.01% 738
2016
Q4 		$4K Buy
+464
New +$3.41K ﹤0.01% 893

Other funds holding ARRY

ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Meeder Asset Management's ARRY Position: Q3 2019 in Review

Meeder Asset Management sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 7,378 shares — an estimated $341K sold.

Meeder Asset Management first reported a position in ARRY in Q4 2016 and held it in 9 quarters. The position peaked at $732K in Q1 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

  • Meeder Asset Management reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
  • Meeder Asset Management sold 7,378 Array Biopharma Inc shares in Q3 2019, an estimated $341K.
  • Meeder Asset Management first reported a position in Array Biopharma Inc in Q4 2016 and held it in 9 quarters.
  • Meeder Asset Management's Array Biopharma Inc position peaked at $732K in Q1 2019.
  • 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Meeder Asset Management's 13F filing for Q3 2019, filed 17 Oct 2019.